We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

23 hedge funds and large institutions have $190M invested in MoonLake Immunotherapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

54% more capital invested

Capital invested by funds: $123M → $190M (+$66.7M)

1.8% more ownership

Funds ownership: 96.95% → 98.75% (+1.8%)

15% less funds holding

Funds holding: 27 → 23 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

Holders
23
Holders Change
-4
Holders Change %
-14.81%
% of All Funds
0.39%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
5
Reduced
2
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$137M
2
CAM
Cormorant Asset Management
Massachusetts
+$17.5M
3
Citadel Advisors
Citadel Advisors
Florida
+$12.6M
4
TCM
TCG Crossover Management
California
+$6.29M
5
RI
RTW Investments
New York
+$3.14M

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$7.9M
2
Marshall Wace
Marshall Wace
United Kingdom
-$7.26M
3
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
-$6.35M
4
BCM
Beryl Capital Management
California
-$5.1M
5
AWG
Alpha Wave Global
New York
-$4.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Beryl Capital Management
California
– -$5.1M -459,243 Closed
AWG
27
Alpha Wave Global
New York
– -$4.49M -448,882 Closed
APM
28
Avidity Partners Management
Texas
– -$4.44M -400,000 Closed
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
– -$3.74M -337,021 Closed
TCM
30
Tekla Capital Management
Massachusetts
– -$2.77M -250,000 Closed
EC
31
EcoR1 Capital
California
– -$2.22M -200,000 Closed
IPCP
32
Iron Park Capital Partners
New York
– -$1.79M -179,434 Closed
WAM
33
Weiss Asset Management
Massachusetts
– -$1.97M -177,510 Closed
CCM
34
Consonance Capital Management
New York
– -$1.52M -137,000 Closed
PMAM
35
Picton Mahoney Asset Management
Ontario, Canada
– -$700K -70,000 Closed
Jane Street
36
Jane Street
New York
– -$726K -65,437 Closed
FTCM
37
Fir Tree Capital Management
New York
– -$619K -61,866 Closed
OAC
38
OMERS Administration Corp
Ontario, Canada
– -$513K -46,247 Closed
Nomura Holdings
39
Nomura Holdings
Japan
– -$239K -22,733 Closed
E
40
Ergoteles
New York
– -$162K -14,613 Closed
CS
41
Clear Street
New York
– -$9K -801 Closed
TRCT
42
Tower Research Capital (TRC)
New York
– +$157 +25 New
1
2

MLTX Hedge Fund Activity: Q2 2022 in Review

23 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2022, worth a combined $190M — up 54% from $123M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of MLTX and 15 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $137M. The largest seller was 683 Capital Management, exiting entirely with an estimated $7.9M sold.

  • 23 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2022, down from 27 in Q1 2022.
  • Funds reported $190M of MoonLake Immunotherapeutics stock for Q2 2022, up 54% quarter-over-quarter.
  • 15 funds opened new MoonLake Immunotherapeutics positions in Q2 2022 and 19 closed out, a net change of -4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2022 was BVF Inc, an estimated $137M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2022 was 683 Capital Management, an estimated $7.9M sold.

Based on aggregated 13F filings for Q2 2022.